Search the Newsreel

Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR)

Capricor Therapeutics has been downgraded to Sell due to mounting FDA doubts regarding the efficacy of its lead product candidate, deramiocel, for DMD cardiomyopathy. The FDA noted that positive endpoints for their HOPE-3 trial were only achieved after post-unblinding SAP changes, compromising statistical validity. …

This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward

Capri Holdings Ltd (CPRI) Institutional Confidence

Capri Holdings Ltd (CPRI) has an institutional shareholding score of 10.00, ranking 1st in the Specialty Retailers industry. The institutional shareholding proportion is 108.35%, indicating a 17.62% decrease quarter-over-quarter. David Einhorn is the largest institutional shareholder, holding 4.75 million shares.

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data

Capricor Therapeutics' shares fell after an FDA briefing document questioned the efficacy of its investigational cell therapy, Deramiocel, for Duchenne muscular dystrophy (DMD) ahead of a key FDA Advisory Committee meeting. The FDA stated that data from studies HOPE-3 and HOPE-2 did not provide …

FDA scientists question Capricor data; Legend CEO steps down

FDA scientists have expressed significant concerns over Capricor Therapeutics' data for its Duchenne muscular dystrophy cell therapy, causing the company's shares to drop sharply. Concurrently, Legend Biotech's CEO, Ying Huang, resigned amidst intense competition in the multiple myeloma market. Meanwhile, AstraZeneca reported mixed results …

Capri Holdings Ltd (CPRI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Capri Holdings Ltd's (CPRI) dividend history and stock splits. It states that the company has distributed $0.00 in dividends over the past five years. The current stock price and market capitalization are also presented.

Capricor plunges on FDA AdCom briefing doc for Duchenne treatment

[Financial crisis down 3d red arrow economy business graph on money crash market background with bankruptcy decrease bad finance chart diagram or loss investment economic recession sales and low price.] Lemon_tm Capricor Therapeutics (CAPR [https://seekingalpha.com/symbol/CAPR]) is down ~67% in Monday morning trading after the …

Capricor Therapeutics shares tumble after FDA reviewers raise concerns over Duchenne therapy

Capricor Therapeutics shares fell by about 67% after FDA staff reviewers expressed concerns regarding the effectiveness of its experimental Duchenne muscular dystrophy therapy, deramiocel. The FDA questioned Capricor's analysis changes post-trial and raised doubts about whether study participants truly had DMD-related cardiomyopathy and if …

Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel

Capricor Therapeutics has issued comments regarding the FDA's briefing materials in anticipation of the upcoming Advisory Committee meeting on July 29, which will discuss the Biologics License Application (BLA) for Deramiocel, a treatment for Duchenne muscular dystrophy (DMD). The company asserts that the FDA's …

Capricor's Duchenne Therapy Heads To FDA Panel Review July 29; Stock Down

(RTTNews) - Capricor Therapeutics, Inc. (CAPR) is approaching a critical moment as the U.S. FDA's Cellular, Tissue, and Gene Therapies Advisory Committee convenes to review its Biologics License Application for Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy cardiomyopathy. Duchenne …

FDA staff flags data concerns about Capricor's therapy; shares plunge

U.S. FDA staff reviewers have raised significant concerns regarding the effectiveness data for Capricor Therapeutics' experimental cell therapy, deramiocel, intended for a heart condition associated with Duchenne muscular dystrophy. These concerns, centered on Capricor's methodology for measuring trial results and the scientific justification for …

SummitTX Capital L.P. Has $10.03 Million Holdings in Capri Holdings Limited $CPRI

SummitTX Capital L.P. significantly increased its stake in Capri Holdings Limited by 222.3% in the first quarter, now holding 569,054 shares valued at approximately $10.03 million. Other institutional investors also adjusted their positions in Capri, with 84.34% of the stock owned by such entities. …

Capricor Therapeutics shares plunge after FDA releases briefing documents

Capricor Therapeutics' shares plummeted 40% after the FDA released briefing documents for a cell therapy candidate aimed at Duchenne muscular dystrophy. The FDA highlighted the need for substantial evidence from at least two adequate clinical studies for approval, noting that Capricor's previous application based …

How FDA‑Linked HQ and Manufacturing Expansion At Capricor Therapeutics (CAPR) Has Changed Its Investment Story

Capri Global Capital posts ₹3,534M net profit in Q1FY26

Is Capricor Therapeutics (CAPR) Trading At A Discount After Its Lease Deal And FDA Wait?

Capricor Therapeutics Inc (CAPR) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure and institutional holdings of Capricor Therapeutics Inc (CAPR). It lists major shareholders like Nippon Shinyaku Co Ltd and Suvretta Capital Management, LLC, along with a breakdown of shareholder types such as hedge funds and investment advisors. The article …

Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel

Capricor Therapeutics (CAPR) has signed a lease for a new headquarters and expanded manufacturing facility, contingent on FDA approval of its Duchenne muscular dystrophy therapy, Deramiocel. This move signals the company's preparation for potential commercialization, with financial arrangements designed to phase in significant operating …

1,349,826 Shares in Capri Holdings Limited $CPRI Bought by Cooper Creek Partners Management LLC

Cooper Creek Partners Management LLC purchased a significant stake of 1,349,826 shares in Capri Holdings Limited, valued at approximately $23.8 million, during the first quarter. This investment comes as Capri reported better-than-expected earnings per share but a substantial 23.1% year-over-year revenue decline. Analyst sentiment …

Capricor Therapeutics (CAPR) Stock Looks Fully Priced For Now

Capral Limited Revenue Breakdown – ASX:CAA

This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy?

Key Points Karen Krasney, EVP, General Counsel, sold 24,100 common shares for a transaction value of ~$732,000 on June 25, 2026, at a weighted average price of around $30.38 per share. The transaction was executed through a derivative exercise (option exercise and immediate sale); …

CPRI|Capri Holdings Ltd|Price:15.440|Chg%:-0.110

Capri Holdings Ltd (CPRI) is currently trading at $15.440, down 0.71%. TradingKey analysis suggests the company has relatively healthy fundamentals and high growth potential, though its valuation is considered fairly valued. Institutional ownership is high, and while analysts have issued "Buy" ratings with a …

CAPR|Capricor Therapeutics Inc|Price:19.700|Chg%:-0.130

Capricor Therapeutics Inc. (CAPR) is a biotechnology company focused on developing cell and exosome-based therapies for rare diseases, particularly Duchenne muscular dystrophy (DMD). Their lead product candidate, deramiocel (CAP-1002), is an allogeneic cardiac-derived cell therapy currently in Phase III clinical development for DMD. The …

Capri Holdings Ltd (CPRI) Valuation: PE, PB & Fair Value Analysis

Capri Holdings Ltd (CPRI) currently holds a valuation score of 7.80, placing it 56th out of 93 companies in the Specialty Retailers industry. The company's P/E ratio stands at -3.62, which is significantly below its recent high and above its recent low. However, relevant …

Capri Holdings Ltd (CPRI) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Capri Holdings Ltd (CPRI), listing its major shareholders and institutional holdings. Key shareholders include Fidelity Management & Research Company LLC and BlackRock Institutional Trust Company, N.A. It also categorizes shareholder types and provides a historical overview of …

Capri Holdings Ltd (CPRI) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Capri Holdings Ltd (CPRI), focusing on its support and resistance levels, various technical indicators, and moving averages. It highlights CPRI's current price momentum score, its trading range between resistance at $18.20 and support at $13.94, and presents …

Capricor Therapeutics, Inc. Revenue Breakdown – NASDAQ:CAPR

This article provides a basic overview of Capricor Therapeutics, Inc. (NASDAQ: CAPR) financial data on TradingView, focusing on its revenue breakdown. It lists categories for financial information, including statements, statistics, dividends, earnings, and segments. The content is primarily a navigational stub with minimal actual …

Stock Traders Purchase Large Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR)

Stock traders recently purchased a significantly high volume of call options for Capricor Therapeutics (NASDAQ:CAPR), signaling increased bullish interest. The company has a "Moderate Buy" consensus rating from analysts with varied price targets, and its stock has been trading below recent moving averages after …

Behavioral Patterns of CAPR and Institutional Flows

This article analyzes Capricor Therapeutics Inc. (NASDAQ: CAPR) focusing on behavioral patterns and institutional flows. It highlights divergent sentiment across various time horizons, suggesting choppy market conditions and elevated downside risk due to a lack of long-term support signals. The analysis provides specific AI-generated …

Implied Volatility Surging for Capri Holdings Stock Options

Implied volatility for Capri Holdings Limited (CPRI) stock options, particularly the Aug. 21, 2026 $7.5 Call, is surging, indicating that the market expects a significant price movement in the near future. This comes as analysts have recently increased their earnings estimates for the company's …

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Rating of "Moderate Buy" by Brokerages

Capricor Therapeutics (NASDAQ:CAPR) has received a "Moderate Buy" consensus rating from 10 brokerages, with an average 1-year price target of $53.67. The stock is currently trading at $19.83, significantly below analyst targets, after reporting a quarterly EPS of ($0.59) which missed estimates. Institutional activity …

Capricorn Metals (ASX:CMM) Drops Today: Investors Weigh Short-Term Weakness Against Long-Term Gains

CAPR Stock On Track To Clock Weekly Gains Ahead Of Critical FDA Panel — Retail Deems It A ‘Binary Event’

Capricor Therapeutics (CAPR) shares are poised for weekly gains ahead of a critical FDA advisory committee meeting on July 29 for its experimental cell therapy, Deramiocel. The treatment targets Duchenne muscular dystrophy, with the FDA expected to make a decision by August 22. Despite …

Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $54

Oppenheimer has reiterated its Buy rating for Capricor Therapeutics (CAPR.US) and maintained its price target at $54. This continued endorsement suggests confidence in the company's future performance.

Capricor Therapeutics (NASDAQ:CAPR) Shares Up 7.4% - Here's What Happened

Capricor Therapeutics (NASDAQ:CAPR) saw its shares rise 7.4% on Thursday, reaching $20.29 with 644,411 shares traded. Analyst sentiment remains mixed but generally bullish, with a consensus target price of $53.67 despite the company missing Q1 earnings estimates with a loss of $0.59 per share. …